Cat.No.:BI-20413
應(yīng)用領(lǐng)域：
1）骨代謝疾病
2）Wnt信號(hào)通路
試劑盒特點(diǎn)：
檢測(cè)方法：夾心ELISA，HRP/TMB顯色
樣本類型：血清
樣品量：20ul/test
標(biāo)準(zhǔn)品范圍：0-160 pmol/L
檢測(cè)靈敏度：1.7pmol/L
孵育條件：2h/1h/30min

產(chǎn)品型號(hào)：

更新時(shí)間：2024-07-05

廠商性質(zhì)：代理商

訪問(wèn)量：1506

服務(wù)熱線

01084640949

立即咨詢

產(chǎn)品分類

PRODUCT CLASSIFICATION

Biomedica Gruppe

抗體5 ELISA試劑盒1 骨代謝心血管疾病

查看全部產(chǎn)品

相關(guān)文章

英國(guó)IDS公司骨切片（ Bone Slices）*~

骨健康檢測(cè)試劑盒全線產(chǎn)品代理

Quidel 補(bǔ)體、骨代謝、糖尿病檢測(cè)試劑一級(jí)代理

Calbiotech 公司檢測(cè)試劑盒

產(chǎn)品介紹

DKK-1檢測(cè)試劑盒

直接測(cè)定，無(wú)需樣本稀釋

貨號(hào)：BI-20413

DKK-1 是Wnt 信號(hào)通路的抑制劑

BI-20413與BI-20412對(duì)比

檢測(cè)特點(diǎn)	BI-20413	BI-20412
孵育時(shí)間	2h/1h/30min	overnight
樣品處理	直接測(cè)定	需要1:4稀釋
標(biāo)準(zhǔn)品范圍	0-160pmol/L	0-50pmol/L

應(yīng)用領(lǐng)域：

骨代謝疾病
Wnt信號(hào)通路

試劑盒特點(diǎn)：

檢測(cè)方法：夾心ELISA，HRP/TMB顯色

樣本類型：血清

樣品量：20ul/test

標(biāo)準(zhǔn)品范圍：0-160 pmol/L

檢測(cè)靈敏度：1.7pmol/L

孵育條件：2h/1h/30min

產(chǎn)品優(yōu)勢(shì)：

當(dāng)日即可檢測(cè)
直接測(cè)定，不許樣品稀釋。
樣本需求量少，只需：20ul
標(biāo)準(zhǔn)品范圍廣
充分證實(shí)可用于人血清樣本檢測(cè)
6個(gè)標(biāo)準(zhǔn)品+1個(gè)對(duì)照（均為血清基質(zhì)）
操作流程簡(jiǎn)單

參考文獻(xiàn)

1	Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin and Dickkopf-1 Levels of Naive Postmenopausal Women With Low Bone Mass: A Randomized, Head-to-Head Clinical Trial. Athanasios D. Anastasilakis, et al. J. Clin. Endocrinol. Metab., Aug 2013; 98: 3206 - 3212.
2	Elevated Serum Dickopff-1 Levels Increase Risk of Hip and Vertebral Fracture in Older Caucasian Women. Aarthi Arasu,et al. Endocr. Rev., Jun 2013; 34: SAT-224.
3	Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. Diederik P C de Rooy,et al. Ann Rheum Dis, May 2013; 72: 769 - 775.
4	High dickkopf-1 levels in sera and leukocytes from children with 21- hydroxylase deficiency on chronic glucocorticoid treatment. Giacomina Brunetti,et al. Am J Physiol Endocrinol Metab, Mar 2013; 304: E546 - E554.
5	Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. D Gatti,et al. J Bone Miner Res, Nov 2012; 27(11): 2259-63.
6	Sclerostin Levels Associated with Inhibition of the Wnt/β-Catenin Signaling and Reduced Bone Turnover in Type 2 Diabetes Mellitus. Agostino Gaudio,et al. J. Clin. Endocrinol. Metab., Oct 2012; 97: 3744 - 3750.
7	Serum Osteoprotegerin, RANKL, and Dkk-1 Levels in Adults with Langerhans Cell Histiocytosis. Polyzois Makras,et al. J. Clin. Endocrinol. Metab., Apr 2012; 97: E618 - E621
8	High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Gisela Ruiz Heiland,et al. Ann Rheum Dis, Apr 2012; 71: 572 - 574.
9	Assessment of circulating Dickkopf-1 with a new two-site immunoassay in healthy subjects and women with breast cancer and bone metastases. N Voorzanger-Rousselot, et al. Calcif Tissue Int, May 1, 2009; 84(5): 348-354
10	Circulating Dickkopf-1 and Radiological Progression in Patients with Early Rheumatoid Arthritis Treated with Etanercept. Patrick Garnero,et al. J Rheumatol, Oct 2008.
11	Increased Sclerostin Serum Levels Associated with Bone Formation and Resorption Markers in Patients with Immobilization-Induced Bone Loss. Agostino Gaudio,et al. J. Clin. Endocrinol. Metab., May 2010; 95: 2248 - 2253.
12	High Serum Sclerostin Correlates with Advanced Stage, Increased Bone Resorption, Reduced Osteoblast Function, and Poor Survival in Newly-Diagnosed Patients with Multiple Myeloma. Evangelos Terpos,et al. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 425.
13	The Effect of Zoledronic Acid on Serum Dickkopf-1, Osteoprotegerin, and RANKL in Patients with Paget's Disease of Bone. S A Polyzos, et al. Horm Metab Res, Aug 2009
14	Glucocorticoids Attenuate the Stimulatory Effect on Bone Formation by Bortezomib. Thomas Lund,et al. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 5183.